HPN328, a tri-specific T cell activating construct (TriTAC®) targeting DLL3, is undergoing a Phase I/II trial to assess safety, tolerability, and pharmacokinetics, both as monotherapy and in combination with atezolizumab, in patients with advanced cancer associated with DLL3 expression. The gene discussed is DLL3; the disease is cancer.